Our early clinical program consists of two phase I studies on healthy subjects and one phase Ib study on patients undergoing open-heart surgery.Read more
We are dedicated to developing tomorrow’s drugs against oxidative stress, helping millions of people to a better life by preventing and treating serious kidney diseases. ROSgard, our biological drug candidate, mimics the body’s own powerful defense system against oxidative stress. Designed with a natural “homing” to the kidneys, ROSgard prevents kidney damage by protecting, cleaning and repairing the exposed cells and tissues.
Guard Therapeutics recently reported positive top-line data from a single ascending dose (SAD) study which demonstrates a favorable safety profile of ROSgard following a single intravenous infusion.
On November 07, Guard Therapeutics presents preclinical data on the protective effects of ROSgard in acute kidney injury models. ROSgard is being developed as a novel and promising therapeutic candidate for the treatment of AKI in cardiac surgery.